Robert Orlowski, Florence Maude Thomas Cancer Research Professor at The University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Final analysis of MAIA patient-reported outcomes finds sustained Improvement in health-related quality of life in transplant-ineligible newly diagnosed myeloma treated with daratumumab/len/dex vs. len/dex doublet.”

“Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported Outcomes”

Authors: Aurore Perrot, Thierry Facon, Torben Plesner, Fredrik Borgsten, Katja Weisel et al.

Myeloma Paper of the Day, February 15th, suggested by Robert Orlowski

More posts featuring Robert Orlowski.